home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Genmab A/S - American Depositary Shares (NQ:GMAB)

29.40 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Feb 24, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Genmab A/S - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Preview: Genmab's Earnings ↗

November 05, 2024

Via Benzinga

NASDAQ:GMAB: a strong growth stock preparing for the next leg up?. ↗

October 30, 2024

Why GENMAB A/S -SP ADR (NASDAQ:GMAB) Is a Promising High-Growth Stock in the Midst of Consolidation.

Via Chartmill

When you look at NASDAQ:GMAB, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. ↗

October 29, 2024

GENMAB A/S -SP ADR (NASDAQ:GMAB) appears to be flying under the radar despite its strong fundamentals.

Via Chartmill

Investors should take note of NASDAQ:GMAB, a growth stock that remains attractively priced. ↗

October 28, 2024

GENMAB A/S -SP ADR (NASDAQ:GMAB) is showing good growth, while it is not too expensive.

Via Chartmill

12 Analysts Have This To Say About Genmab ↗

October 16, 2024

Via Benzinga

NASDAQ:GMAB qualifies as a high growth stock and is consolidating. ↗

October 09, 2024

GENMAB A/S -SP ADR (NASDAQ:GMAB)—Positioned as a High-Growth Stock, Ready for a Potential Breakout.

Via Chartmill

NASDAQ:GMAB is an undervalued gem with solid fundamentals. ↗

October 08, 2024

Don't overlook GENMAB A/S -SP ADR (NASDAQ:GMAB)—it's a hidden gem with strong fundamentals and an attractive price tag.

Via Chartmill

NASDAQ:GMAB, a growth stock which is not overvalued. ↗

October 07, 2024

NASDAQ:GMAB is showing good growth, while it is not too expensive.

Via Chartmill

NASDAQ:GMAB is probably undervalued for the fundamentals it is displaying. ↗

September 17, 2024

GENMAB A/S -SP ADR (NASDAQ:GMAB) is an undervalued gem with solid fundamentals.

Via Chartmill

Expert Ratings For Genmab ↗

September 09, 2024

Via Benzinga

Jin Medical International, Nio And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

September 23, 2024

Via Benzinga

Don't overlook NASDAQ:GMAB—a stock with solid growth prospects and a reasonable valuation. ↗

September 16, 2024

Don't overlook NASDAQ:GMAB—a stock with solid growth prospects and a reasonable valuation.

Via Chartmill

Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial

September 15, 2024

From Genmab A/S

Via Business Wire

NASDAQ:GMAB: a strong growth stock preparing for the next leg up?. ↗

September 03, 2024

Is GENMAB A/S -SP ADR (NASDAQ:GMAB) on the Verge of a Major Breakout as a Strong Growth Stock?

Via Chartmill

NASDAQ:GMAB is showing good growth, while it is not too expensive. ↗

August 26, 2024

GENMAB A/S -SP ADR (NASDAQ:GMAB) is not too expensive for the growth it is showing.

Via Chartmill

Decoding 10 Analyst Evaluations For Genmab ↗

August 20, 2024

Via Benzinga

Is NASDAQ:GMAB on the Verge of a Major Breakout as a Strong Growth Stock? ↗

August 05, 2024

Why GENMAB A/S -SP ADR (NASDAQ:GMAB) Is a Promising High-Growth Stock in the Midst of Consolidation.

Via Chartmill

TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

August 19, 2024

From Genmab A/S

Via Business Wire

Genmab Announces Changes to its Executive Committee

August 16, 2024

From Genmab A/S

Via Business Wire

On Holding Reports Mixed Q2 Results, Joins Tencent Music Entertainment And Other Big Stocks Moving Lower In Tuesday Pre-Market Session ↗

August 13, 2024

Via Benzinga

What 8 Analyst Ratings Have To Say About Genmab ↗

August 01, 2024

Via Benzinga

What 8 Analyst Ratings Have To Say About Genmab ↗

July 15, 2024

Via Benzinga

NASDAQ:GMAB, an undervalued stock with good fundamentals. ↗

July 01, 2024

GENMAB A/S -SP ADR (NASDAQ:GMAB) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.

Via Chartmill

GMAB Stock Earnings: Genmab Misses EPS, Beats Revenue for Q2 2024 ↗

August 08, 2024

GMAB stock results show that Genmab missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.

Via InvestorPlace

BioNTech's Q2 Loss Widens Amid Low Demand For Its Pfizer-Partnered COVID-19 Vaccine, Increases R&D Spending On New Cancer Products ↗

August 05, 2024

BioNTech posted a significant Q2 2024 loss of 807.8 million euros. Sales dropped to 128.7 million euros as the demand for COVID-19 vaccines shifted. R&D expenses rose due to late-stage oncology...

Via Benzinga

While growth is established for NASDAQ:GMAB, the stock's valuation remains reasonable. ↗

August 05, 2024

While growth is established for NASDAQ:GMAB, the stock's valuation remains reasonable.

Via Chartmill

Investors should take note of NASDAQ:GMAB, a growth stock that remains attractively priced. ↗

July 15, 2024

GENMAB A/S -SP ADR (NASDAQ:GMAB) is showing decent growth, but is still valued reasonably.

Via Chartmill

Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma

June 28, 2024

From Genmab A/S

Via Business Wire

AbbVie/Genmab's Epkinly FDA Approval Is A Positive Step, Analyst Says Additional Expansion Opportunities Underway ↗

June 27, 2024

The FDA has approved Epkinly as the first subcutaneously administered bispecific antibody for adults with relapsed or refractory follicular lymphoma after two or more lines of prior therapy.

Via Benzinga

EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

June 26, 2024

From Genmab A/S

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com